News

Fast Track designation is granted to facilitate and expedite development and review for drugs that are intended to treat a serious condition and with nonclinical or clinical data

Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or

Myriam Delvaux, global pharmaceutical marketing leader for Dow Corning Healthcare will lead the webinar and explain how silicone-based ingredients and excipients can help generate innovative product forms with

The company acquired six OTC brands from Ducere Pharma, including DOAN’S, BUFFERIN, NUPERCAINAL Ointment, CRUEX Nail Gel, COMTREX, and MYOFLEX. "These legacy products enjoy strong brand equity built

Arrivo was founded by Steve Butts, Bill Wofford, Dr. Michael Ackermann and Dr. Jed Black, and located in North Carolina’s Research Triangle Park region. Mr. Butts and Mr.

It is intended that ABLS Capital, LLC, which includes Allied Minds, Woodford Investment Management and Invesco Asset Management among its investors, will fund 80% of this phase of

These findings on BAX 930 were presented during a poster session at the 62nd annual Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and

About 500 patients will be enrolled in the randomized, double-blind, placebo-controlled phase 3 study, dubbed Cascade, which will assess 33A in combination with azacitidine (Vidaza) or decitabine (Dacogen)

The 15-member panel of the Endocrinologic and Metabolic Drugs Advisory Committee voted 12 to 2 (1 panelist did not vote due to travel) to approve the combination. Two